Evommune, Inc. (EVMN) stock declined over -0.67%, trading at $13.25 on NYSE, down from the previous close of $13.34. The stock opened at $13.16, fluctuating between $12.96 and $14.01 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 13.16 | 14.11 | 12.96 | 13.25 | 1.14M |
| Jul 07, 2026 | 12.48 | 13.84 | 12.36 | 13.34 | 1.92M |
| Jul 06, 2026 | 13.03 | 13.41 | 12.07 | 12.36 | 968.25K |
| Jul 02, 2026 | 12.97 | 13.90 | 12.51 | 12.96 | 1.34M |
| Jul 01, 2026 | 13.27 | 13.82 | 12.65 | 12.82 | 1.61M |
| Jun 30, 2026 | 14.76 | 15.00 | 13.18 | 13.29 | 1.75M |
| Jun 29, 2026 | 17.54 | 18.30 | 14.98 | 15.05 | 10.45M |
| Jun 26, 2026 | 23.85 | 25.87 | 23.85 | 25.18 | 1.4M |
| Jun 25, 2026 | 23.42 | 24.73 | 22.92 | 24.13 | 492.26K |
| Jun 24, 2026 | 24.14 | 25.52 | 23.33 | 23.56 | 1.04M |
| Jun 23, 2026 | 22.38 | 24.49 | 22.31 | 24.25 | 716.12K |
| Jun 22, 2026 | 21.50 | 23.13 | 21.35 | 22.55 | 517.38K |
| Jun 18, 2026 | 21.00 | 21.45 | 20.05 | 21.36 | 665.02K |
| Jun 17, 2026 | 20.24 | 20.94 | 19.73 | 20.65 | 602.9K |
| Jun 16, 2026 | 20.90 | 20.92 | 19.98 | 20.05 | 344.58K |
| Jun 15, 2026 | 20.10 | 21.24 | 19.83 | 20.84 | 447.55K |
| Jun 12, 2026 | 20.67 | 21.61 | 19.77 | 19.83 | 462.65K |
| Jun 11, 2026 | 20.31 | 21.15 | 20.13 | 20.69 | 810.35K |
| Jun 10, 2026 | 20.33 | 21.52 | 20.13 | 20.49 | 562.9K |
| Jun 09, 2026 | 20.21 | 21.08 | 19.42 | 20.49 | 378.89K |
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
| Employees | 45 |
| Beta | 0.86 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep